Mylan N.V. (MYL) Earning Somewhat Favorable News Coverage, Study Finds
Press coverage about Mylan N.V. (NASDAQ:MYL) has trended somewhat positive on Monday, Accern reports. Accern identifies negative and positive media coverage by analyzing more than twenty million news and blog sources in real time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Mylan N.V. earned a media sentiment score of 0.18 on Accern’s scale. Accern also assigned press coverage about the company an impact score of 44.7708367325105 out of 100, meaning that recent media coverage is somewhat unlikely to have an impact on the company’s share price in the next several days.
These are some of the media headlines that may have effected Accern Sentiment Analysis’s analysis:
- Mylan N.V. (MYL) Price Target Increased to $45.00 by Analysts at BTIG Research (americanbankingnews.com)
- Mylan N.V.’s (MYL) “Hold” Rating Reaffirmed at Cantor Fitzgerald (americanbankingnews.com)
- Mylan’s FDA Approval Isn’t All That: Wells Fargo – Investopedia (investopedia.com)
- Mylan N.V. (MYL) Price Target Raised to $39.00 (americanbankingnews.com)
- UPDATE 1-Teva’s Copaxone faces generic competition in Europe after US hit – Business Insider (businessinsider.com)
Mylan N.V. (NASDAQ:MYL) opened at 38.29 on Monday. The firm’s 50-day moving average is $32.08 and its 200 day moving average is $36.45. Mylan N.V. has a 1-year low of $29.39 and a 1-year high of $45.87. The stock has a market capitalization of $20.53 billion, a price-to-earnings ratio of 30.95 and a beta of 1.30.
Mylan N.V. (NASDAQ:MYL) last issued its earnings results on Wednesday, August 9th. The company reported $1.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $1.18 by ($0.08). Mylan N.V. had a return on equity of 22.42% and a net margin of 5.51%. The company had revenue of $2.96 billion during the quarter, compared to analyst estimates of $3 billion. During the same period last year, the business earned $1.16 earnings per share. The firm’s revenue was up 15.7% compared to the same quarter last year. Equities analysts anticipate that Mylan N.V. will post $4.57 EPS for the current fiscal year.
A number of research firms have commented on MYL. Cowen and Company restated a “hold” rating and set a $30.00 target price (down previously from $43.00) on shares of Mylan N.V. in a research note on Wednesday, August 9th. Cantor Fitzgerald set a $34.00 target price on shares of Mylan N.V. and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Wells Fargo & Company set a $30.00 target price on shares of Mylan N.V. and gave the stock a “hold” rating in a research note on Wednesday, August 9th. Royal Bank Of Canada restated a “sector perform” rating and set a $32.00 target price (down previously from $33.00) on shares of Mylan N.V. in a research note on Thursday, August 10th. Finally, BMO Capital Markets restated an “outperform” rating and set a $45.00 target price (down previously from $50.00) on shares of Mylan N.V. in a research note on Thursday, August 10th. One investment analyst has rated the stock with a sell rating, nine have assigned a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $41.99.
ILLEGAL ACTIVITY NOTICE: This piece was originally reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this piece on another website, it was illegally stolen and republished in violation of United States and international copyright and trademark law. The legal version of this piece can be accessed at https://www.thecerbatgem.com/2017/10/09/mylan-n-v-myl-earning-somewhat-favorable-news-coverage-study-finds.html.
Mylan N.V. Company Profile
Mylan N.V. is a global pharmaceutical company. The Company develops, licenses, manufactures, markets and distributes generic and branded generic products for resale by others; specialty pharmaceuticals, and active pharmaceutical ingredients (APIs). It operates through two segments: Generics and Specialty.
Receive News & Stock Ratings for Mylan N.V. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mylan N.V. and related stocks with our FREE daily email newsletter.